You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Type-specific prevalence of oncogenic HPV infection in all women with an index high grade cytology

From: Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand

  High grade cytology (ASC-H/HSIL/AGC/AIS)
  Māori (N=241) Non-Māori (N=489) Overall (N=730)
HR HPV type N % 95 % CI N % 95 % CI N % 95 % CI
HPV16 (any) 119 49 (43–56) 208 43 (38–47) 327 45 (41–48)
HPV52 (any) 29 12 (8–17) 84 17 (14–21) 113 15 (13–18)
HPV31 (any) 33 14 (10–19) 75 15 (12–19) 108 15 (12–18)
HPV33 (any) 20 8 (5–13) 58 12 (9–15) 78 11 (9–13)
HPV18 (any) 31 13 (9–18) 54 11 (8–14) 85 12 (9–14)
HPV58 (any) 22 9 (6–13) 53 11 (8–14) 75 10 (8–13)
HPV51 (any) 21 9 (6–13) 43 9 (6–12) 64 9 (7–11)
HPV39 (any) 16 7 (4–11) 33 7 (5–9) 49 7 (5–9)
HPV45 (any) 9 4 (2–7) 24 5 (3–7) 33 5 (3–6)
HPV59 (any) 12 5 (3–9) 23 5 (3–7) 35 5 (3–7)
HPV35 (any) 9 4 (2–7) 18 4 (2–6) 27 4 (3–5)
HPV56 (any) 12 5 (3–9) 12 3 (1–4) 24 3 (2–5)
HPV68 (any) 1 0 (0–2) 15 3 (2–5) 16 2 (1–4)
HPV16 and/or 18 (any) 141 59 (52–65) 252 52 (47–56) 393 54 (50–57)
 HPV16 with HPV18 (any) 9 4 (2–7) 9 2 (1–4) 18 3 (2–4)
 HPV16 without HPV18 (any) 110 46 (39–52) 199 41 (36–45) 309 42 (39–46)
 HPV18 without HPV16 (any) 22 9 (6–13) 44 9 (7–12) 66 9 (7–11)
HPV16 and/or 18 (without OHR) 88 37 (30–43) 115 24 (20–28) 203 28 (25–31)
HPV16 and/or 18 (with OHR) 53 22 (17–28) 137 28 (24–32) 190 26 (23–29)
OHR without HPV 16/18 82 34 (28–40) 171 35 (31–39) 253 35 (31–38)
HR HPV (single infection) 137 57 (50–63) 212 43 (39–48) 349 48 (44–52)
HR HPV (any) 222 92 (88–95) 423 87 (83–89) 645 88 (86–91)
HPV positive (including LR HPV) 229 95 (91–97) 450 92 (89–94) 679 93 (91–95)
  1. HR high risk, LR low risk, OHR Other high risk, excluding HPV 16 or 18; any – regardless of co-infection with other HPV types
  2. HR HPV includes infection with either type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68
  3. P values for differences were not calculated for each specific HPV type between Māori and non-Māori women due to sample size limitations and concerns about multiple comparisons